
![]() |
|||||||||||||
WJPR Citation
|
| All | Since 2020 | |
| Citation | 8502 | 4519 |
| h-index | 30 | 23 |
| i10-index | 227 | 96 |
REVIEW ARTICLE ON SULFONAMIDE DERIVATIVE AS DPP-4 INHIBITOR
Dr. Shailaja B. Jadhav* and Megha Salve
Abstract Diabetes is chronic metabolic disorder which growing fast ground world. Dipeptidyl peptidase IV (DPP4) inhibitors are proven in the treatment of type 2 diabetes. DPP-4 is a target during controlling diabetes glycemic control. DPP‐4 inhibitors have been shown to be generally well tolerated, with a low risk of hypoglycemia and neutral weight gain, and have anticipated long‐term beneficial effects on β‐cell function. A number of DPP-4 inhibitor develop rapidly for management of type-2 diabetes. This article review development of synthetic sulphonamide derivative as a DPP-4 inhibitor from 2004 to 2017 and provide SAR, biological activities against DPP-4and selectivity over DPP-8/DPP-9. Keywords: DPP4 inhibitors, Sulfonamide derivative, type 2 diabetes. [Full Text Article] [Download Certificate] |
